Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
- 1 March 2019
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 73 (3) , 354-362
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharmaceutical
This publication has 26 references indexed in Scilit:
- Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney diseaseKidney International, 2014
- Advances in Understanding the Urine-Concentrating MechanismAnnual Review of Physiology, 2014
- Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney diseaseKidney International, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male VolunteersCardiovascular Drugs and Therapy, 2011
- A Case for Water in the Treatment of Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Unified Criteria for Ultrasonographic Diagnosis of ADPKDJournal of the American Society of Nephrology, 2009
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2008
- Impact of Solute Intake on Urine Flow and Water ExcretionJournal of the American Society of Nephrology, 2008
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006